On September 28, 2018 Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA) constructs as gene regulatory and immunotherapeutic agents, reported that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Ladenburg Thalmann 2018 Healthcare Conference and Leerink Partners Roundtable Series: Rare Disease & Oncology. Details of these presentations are as follows (Press release, Exicure, SEP 28, 2018, View Source [SID1234529650]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ladenburg Thalmann 2018 Healthcare Conference

Date/Time: Tuesday, October 2, 2018 at 2:00 p.m. EDT
Location: Sofitel Hotel, New York City
Leerink Partners Roundtable Series: Rare Disease & Oncology

Date/Time: Wednesday, October 3, 2018 at 9:30 a.m. EDT
Location: Lotte New York Palace, New York City
A live webcast of these presentations will be available on the Events & Presentations section of Exicure’s website, where it will also be archived and available for replay following the presentation for 30 days.